Looking for a Washington, DC Sinemet attorney? Get in touch with one of our Washington, DC Sinemet attorneys now.
Sinemet - News Articles
-
Jan 16, 2007
Houston Chronicle, TX -
© 2007 AP. BERLIN — Drug maker Schwarz Pharma AG said Tuesday that its Neupro treatment for Parkinson's disease has received approval in Europe to treat the illness in its advanced stages. The drug was first approved in March 2006 in Europe to ... -
Jan 16, 2007
BusinessWeek -
Drug maker Schwarz Pharma AG said Tuesday that its Neupro treatment for Parkinson's disease has received approval in Europe to treat the illness in its advanced stages. The drug was first approved in March 2006 in Europe to treat early stages ... -
Jan 16, 2007
Forbes, NY -
AP 01.16.07, 5:52 PM ET. Drug maker Schwarz Pharma AG said Tuesday that its Neupro treatment for Parkinson's disease has received approval in Europe to treat the illness in its advanced stages.The drug was first approved in March 2006 in Europe to treat early ... -
Thursday, January 18, 2007
PharmaLive.com (press release), PA -
HAYWARD, Calif.--(BUSINESS WIRE)--Jan 18, 2007 - IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has filed an amendment to its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its Vadova(TM) (carbidopa/levodopa) tablets. The Company believes that ... -
Thursday, January 18, 2007
Genetic Engineering News (press release), NY -
IMPAX Laboratories, Inc. (OTC:IPXL) today announced that it has filed an amendment to its new drug application (NDA) with the US Food and Drug ... -
Dec 22, 2006
PharmaLive.com (press release), PA -
both initial monotherapy and as an adjunctive therapy to levodopa and by the completion of enrollment of this very important trial," said Larry Downey, ... -
Dec 22, 2006
PR Newswire (press release), NY -
The effectiveness of AZILECT as adjunct therapy was shown in patients with PD who were treated with levodopa. -- Patients should not take AZILECT if they are currently taking meperidine as it could possibly result in a serious reaction ... -
Jan 2, 2007
MedIndia, India -
the scientific journal of the American Academy of Neurology, was observed when patients not responding to the usual prescribed drug levodopa, were given varied doses of zonisamide, a drug used in the treatment of epilepsy."Zonisamide treatment improved all main Parkinson disease symptoms ... -
Jan 2, 2007
Therapeutics Daily (subscription) (press release), PA -
2 issue of Neurology, included 279 Parkinson's patients who were not responding well to the commonly used drug, levodopa, to manage their symptoms. The participants were randomly assigned to take 25, 50 or 100 milligrams a day of the drug zonisamide, or ... -
Dec 11, 2006
In-PharmaTechnologist.com, France -
The research team, lead by Maaike Kroon, at Delft University of Technology has worked on a novel ionic liquid method to manufacture levodopa, the most common drug treatment for PD sufferers.PD is a lucrative market for drugmakers, with an ever-growing elderly population, ...
-
Jan 2, 2007
MedPage Today, NJ -
Patients with Parkinson's disease resistant to levodopa who received Zonegran in two of three different doses had significant improvements in Parkinson's ... -
Jan 4, 2007
WebMD -
They note that the patients had been taking levodopa doses lower than those typically used in the US, but said they probably weren't undertreated. ... -
Jan 2, 2007
News-Medical.net, Australia -
The three-month, multi-center study in Japan involved 279 Parkinson disease patients who weren't responding well to the commonly used drug, levodopa, to manage their symptoms. The patients were divided into groups that took 25, 50 or 100 mg a day ... -
Wednesday, December 06, 2006
Focus (subscription) -
Most drugs are prescribed for several illnesses, but it took several years for psychotropic drugs to have multiple clinical indications. ... -
Wednesday, December 06, 2006
Focus (subscription) -
This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the ... -
Wednesday, December 06, 2006
Focus (subscription) -
Roy H. Perlis, MD , Michael J. Ostacher, MD, MPH , Jayendra K. Patel, MD , Lauren B. Marangell, MD , Hongwei Zhang, MD, MS , Stephen R. Wisniewski, Ph.D ... -
Oct 31, 2006
Forbes, NY -
Most early-stage patients respond well to the drug levodopa, which is converted in the brain into dopamine, or to "dopamine agonists" that activate the brain's dopaminereceptors.But as the disease progresses and more and more brain cells arelost, patients require more drugs at higher doses ... -
Nov 10, 2006
FinanzNachrichten.de, Germany -
research first approved in 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's Disease, as monotherapy or in combination with levodopa. Pramipexole was approved in April 2006 throughout the European Union for the symptomatic treatment of moderate to ... -
Nov 6, 2006
Pittsburgh Tribune-Review, PA -
medication. The tried and pretty much true dopamine replacement, which is commonly referred to as Sinemet, is a mainstay for many. A small group of medicines called dopamine agonists, which were approved for use several years ago, are usually effective; ... -
Oct 30, 2006
Human Events, DC -
off medication. Equivalent levodopa intake was reduced by 50%,” wrote Gary Vogin, MD of Levesque’s results in Medscape. Last ...
Looking for a Washington, DC Sinemet attorney? Get in touch with one of our Washington, DC Sinemet attorneys now.
Pages: Previous ... 2 3 4 5 6 7 8 Next
